The safety, efficacy and cost-effectiveness of the Maxm Skate, a lower limb rehabilitation device for use following total knee arthroplasty: study protocol for a randomised controlled trial by Liptak, Matthew G et al.
STUDY PROTOCOL Open Access
The safety, efficacy and cost-effectiveness
of the Maxm Skate, a lower limb
rehabilitation device for use following total
knee arthroplasty: study protocol for a
randomised controlled trial
Matthew G. Liptak1*, Annika Theodoulou2,3,4, Billingsley Kaambwa5, Steve Saunders6, Scott W. Hinrichs7,
Richard J. Woodman8 and Jeganath Krishnan2,3
Abstract
Background: Physical rehabilitation is required to enhance functional outcomes and overall recovery following
total knee arthroplasty (TKA). However, there are no universally accepted clinical guidelines available to
consistently structure rehabilitation for TKA patients. A common method is rehabilitation provided in an
outpatient setting, on a one-to-one treatment basis. This method is resource-intensive and outcomes must
be compared to less costly alternatives such as home-based rehabilitation. The current study will analyse a
novel home-based rehabilitation program. The Maxm skate is a portable, lower-limb, postoperative, rehabilitation
exercise device for individual use in a hospital or home-based setting. This study was developed to compare the safety,
efficacy and cost-effectiveness of the Maxm Skate rehabilitation program to standard rehabilitative care following TKA.
The primary outcome is the range of motion (ROM) achieved by patients who received the Maxm Skate program
compared to standard care at three months post TKA. Secondary outcomes include patient-reported outcomes,
costs and functional evaluations which will be collected at multiple time-points up to 12 months after TKA.
Methods: This is a single-blinded, randomised controlled trial (RCT) in which 116 eligible participants consented
for primary TKA will be randomly allocated to receive either the Maxm Skate rehabilitation program or standard
rehabilitative care. Fifty-eight participants per group will provide 90% power (α = 0.05) to detect 10° of difference
in ROM between groups at three months after TKA, assuming a within-group standard deviation of 16° and allowing
for 5% loss to follow-up. Participants randomised to the Maxm Skate group will use the skate device and
accompanying iOS App and sensors to complete rehabilitation exercises, as outlined in the Maxm Skate
Rehabilitation Guide. Outcomes will be compared to those receiving standard rehabilitative care.
A blinded physiotherapist will evaluate functional outcomes preoperatively and at 2, 4, 6, 12, 26 and 52 weeks
after TKA. The functional assessment will include measures of knee ROM, pain, isometric knee strength, balance and
knee/thigh circumference. Limited measures will also be assessed at day 2 postoperatively by an alternate,
unblinded physiotherapist. Clinical outcome measures will be administered preoperatively and at 6, 12 and 52
weeks postoperatively. An economic evaluation will be conducted and participants will be screened for adverse
event occurrences from the time of consent to 12months postoperatively.
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Discussion: This RCT will be the first to investigate the safety, efficacy and cost-effectiveness of the home-based Maxm
Skate Rehabilitation program, in comparison to standard rehabilitative care following primary TKA.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12616001081404p. Registered on 11 August
2016.
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Background
Primary total knee arthroplasty (TKA) is an increasingly
common surgical intervention used to alleviate pain and
physical dysfunction associated with end-stage degenera-
tive joint disease. Following surgery, patients experience
lower-extremity muscle weakness and commonly require
physical rehabilitation to enhance functional outcomes
and overall recovery [1, 2]. While TKA is a successful
procedure for many patients, up to 15–20% of patients
remain unsatisfied [3, 4]. Limited postoperative range of
motion (ROM), which is often associated with arthrofi-
brosis, may be one factor associated with patient dissat-
isfaction. The recorded incidence of arthrofibrosis after
primary TKA varies in the literature, in the range of ap-
proximately 1–13% [4–6]. When it occurs, it is a signifi-
cant cause of patient dissatisfaction associated with poor
ROM and is a causative factor of revision TKA [5, 6].
Therefore, as limited ROM is an early indicator of po-
tential arthrofibrosis, rehabilitation that enables ongoing
flexion/extension exercises and ongoing collection of
such progress, may improve early detection of arthrofi-
brosis and as such appropriate rehabilitative manage-
ment before the need for revision surgery. In addition, it
is well established that daily activities including climbing
stairs and standing from a chair require 90–120° of
flexion, kneeling and squatting 110–165°, 135° of flexion
to lift from a bath and > 150° for yoga or gardening [7–9].
However, patients rarely achieve > 120° of flexion post
TKA and 110° of flexion is an optimal goal for rehabili-
tation following TKA [9–11]. At present, there are no
universally accepted or widely implemented clinical
guidelines available to consistently structure patient re-
habilitation following TKA [12–14]. Consequently, re-
habilitative protocols are not standardised and regularly
based on institution-, surgeon- or occasionally, patient-
specific preferences [1, 2, 12]. This lack of uniformity in
the mode of rehabilitation results in therapy of different
types, frequency, intensity and duration across sites and
countries [1, 2].
In Australia, rehabilitation most commonly provided
is in an outpatient setting, on a one-to-one treatment
basis [12]. Outpatient physiotherapy in a clinic-based
setting is beneficial as a physiotherapist can monitor
progress and modify therapy; however, such methods
are resource-intensive and impose a significant cost
burden [2]. Further concerns include patient transpor-
tation to clinics following surgery and accessibility to
qualified rehabilitative specialists.
In 2016, the number of primary TKA procedures per-
formed in Australia increased by 139.8% since 2003 and
by 2.8% compared to 2015 [15]. Such trends suggest that
TKA use will continue to rise, bringing concern of the
sustainability and economic impact of one-to-one rehabili-
tation commonly employed. There is a need to determine
whether such outpatient physiotherapy yields superior
outcomes compared to less costly alternate forms such as
group-based, home-based or tele-rehabilitation.
Several randomised controlled trials (RCT) have con-
sidered the influence of outpatient physiotherapy on
functional outcomes following TKA. Mockford et al.
[16] and Rajan et al. [17] both concluded no significant
difference in ROM achieved between patients who did
and did not receive outpatient physiotherapy 12 months
after TKA. However, methodologically short-comings,
and limited descriptions of the standard outpatient
physiotherapy provided, caused a literature reviewer to
suggest that conclusions from these studies were not
supported [2]. A methodologically robust RCT found
that one-to-one outpatient treatment provided over a
six-week period did not provide superior self-reported
or performance-based outcomes, compared to group-
based or monitored home programs up to 12 months
after TKA [18]. Furthermore, a recent meta-analysis
demonstrated no difference in knee ROM and short-
term functional improvements between outpatient
physiotherapy in a clinic-based setting and non-supervised
home-based exercise regimens following discharge after
TKA [19].
The common provision of one-to-one therapy is not
currently supported over more economical home-based
rehabilitative methods of which elicit similar self-re-
ported, functional and performance-based outcomes
[18, 20]. The current study will analyse a novel home-
based rehabilitation program as compared to the stand-
ard rehabilitative care options available to patients. As
detection of arthrofibrosis is typically first observed
through reduced postoperative ROM, it is particularly
important to this study to collect ROM data. Further-
more, early detection of poor ROM (three months) may
enable implementation of appropriate rehabilitation
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before the requirement of manipulation under anaes-
thesia (MUA) or revision surgery.
The Maxm Skate device is a portable, lower-limb,
postoperative and post-injury rehabilitation exercise de-
vice for individual use in a hospital or home-based set-
ting. The Maxm Skate intends to facilitate rehabilitation
and conditioning of the lower limb through graded
therapeutic exercise with the aim to promote tissue heal-
ing, remodelling and strengthening. It allows the patient
to perform strengthening exercises with minimal joint
loading during their rehabilitation period.
The Maxm Skate package comprises the Skate device
and rope (for assisted active motion and resistance train-
ing), sensors, iOS Application (App) and website. The
Skate device is accompanied by two sensors and a mo-
bile App which are designed to provide real-time, object-
ive data on exercise and rehabilitation progress, in
particular ROM following each home-based exercise
therapy session. This sensor technology also enables the
clinician to monitor accurate compliance and ROM data
(Flexion and Extension) remotely.
This clinical trial is the first to compare the safety, effi-
cacy and cost-effectiveness of the Maxm Skate rehabili-
tation package to standard rehabilitative care up to 12
months after TKA.
Objectives
The primary objective of this RCT is to assess the ROM
achieved by TKA patients whom received the Maxm
Skate rehabilitation package compared with standard re-
habilitative care, three months postoperatively.
Secondary objectives include the comparison of func-
tional, clinical and performance-based outcome measures
between the Maxm Skate and standard rehabilitative care
groups at multiple times points, up to 12months after
TKA. An economic evaluation assessing the relative cost-
effectiveness of the Maxm Skate rehabilitation package
compared to standard care will be conducted; patients
will be screened for adverse event (AE) occurrences
and complications from the time of consent to one year
postoperatively.
Methods/Design
This is a single-blinded RCT comparing the safety, effi-
cacy and cost-effectiveness of the Maxm Skate Rehabili-
tation Program to standard rehabilitative care following
TKA.
Study setting
The study will be coordinated by the International
Musculoskeletal Research Institute Inc. at the study
site, Flinders Private Hospital (FPH), Bedford Park,
South Australia.
Recruitment and selection criteria
Consecutive patients consented for elective primary
TKA at a single orthopaedic surgeon’s private clinic will
be screened for eligibility. The treating surgeon (MGL)
will screen all patients against the selection criteria and
document reasons for ineligibility in the patient screen-
ing log. Study inclusion criteria include:
1. The patient requires a primary TKA due to
non-inflammatory degenerative joint disease (e.g.
osteoarthritis and traumatic arthritis) or inflammatory
joint disease (e.g. rheumatoid arthritis).
2. The patient must understand the conditions of the
study and be willing and able to provide written
informed consent.
3. The patient is a skeletally mature man or a non-
pregnant woman, aged ≥ 30 years.
4. The patient agrees to comply with the specified
preoperative and postoperative study requirements.
Study exclusion criteria include:
1. The patient has an emotional or neurological
condition that would pre-empt their ability to
participate in the study including mental illness,
intellectual disability and drug or alcohol abuse.
2. Any patient who is unable to meet the requirements
of the use of the Maxm Skate Rehabilitation Device.
3. The patient is unable to perform home exercise
program without supervision or assistance.
A clinical nurse or authorised delegate will invite eli-
gible patients to come in to discuss the study. Patients
will be informed of the study purpose and the potential
risks and benefits known, or that can be reasonably pre-
dicted, as outlined in the Participant Information Sheet.
The patient will then be given the opportunity to ask
any clarifying questions and invited to complete the
consent form, indicating their understanding of the
study and consent for participation. Following consent,
participants will be randomised and baseline measures
obtained. The randomisation number will be used to
provide anonymous identification of the participant on
study documents from there forth.
Randomisation and blinding
The randomisation schedule will be prepared using
numbered and sealed, opaque envelopes. Participants
will be randomly allocated in a 1:1 ratio to either the
‘Maxm Skate Rehabilitation Program’ or the ‘Standard
Rehabilitative Care’ group. Block randomisation in
groups of four will be used to ensure balance in the two
groups. Randomisation will also be stratified by gender
to ensure balance between groups for each gender. We
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note that the number of women undergoing TKA for
osteoarthritis has been shown to be greater in Australia
[21]. In addition, studies have demonstrated that there
are differences between men and women in muscle and
physical function recovery after TKA [22, 23].
The study will be single-blinded with blinding of study
investigators but not participants. Participant randomisa-
tion to either Maxm Skate or Standard Care will be per-
formed by the unblinded Study Coordinator, who will
hold the treatment allocation code in confidence. The
statistician will be blinded to the treatment allocation
code when performing all analyses. Functional evalua-
tions and performance tests will be conducted by a
trained physiotherapist (SWH) who will be blinded to
group allocation. This blinded physiotherapist will con-
duct all functional evaluations, excluding postoperative
day 2, due to practical constraints. Non-blinded ward-
based physiotherapists will conduct the day 2 assess-
ments, as well as the preoperative Maxm Skate educa-
tion session for participants allocated to the Maxm
Skate group.
Due to the nature of the intervention there is a poten-
tial for participants to disclose, or physiotherapist to
gauge, which group the participants are assigned. Partici-
pants will be educated and instructed not to advise the
physiotherapist or treating surgeon of their group as-
signment at the time of their consent and randomisation
with the unblinded Study Coordinator. However, if par-
ticipants are concerned about their rehabilitative pro-
gress and feel it is necessary to discuss this with their
treating surgeon, they will be able to do so. The breaking
of blinding will be collected and reviewed during data
analysis.
Interventions
All participants will undergo primary TKA at Flinders
Private Hospital. All hospital TKA patients are invited to
attend a ‘Joint replacement information session’ which
provides further education and the opportunity for
physiotherapy and nursing staff to address patient quer-
ies. An exercise booklet is issued describing the postop-
erative exercises and patients are asked to familiarize
themselves with the exercises.
Maxm Skate rehabilitation program
Participants randomised to the Maxm Skate rehabilita-
tion program will be required to use the skate device
and accompanying iOS App and sensors to complete re-
habilitation exercises, as outlined in the Maxm Skate Re-
habilitation Guide (see Additional file 1). Participants
will be asked to download the Maxm Skate App on an
iOS device, which will be provided if a personal device is
not available.
Clinical data will be collected via the App aligns with
the exercises outlined in the rehabilitation guide, includ-
ing exercises completed, number of repetitions, length of
time completing exercise and outcomes achieved. Data
collected via the App are stored in the Google Firestore
cloud database and within the iOS device itself.
Preoperative phase Participants will attend a preopera-
tive device education session where they will be intro-
duced to the Maxm Skate program by a physiotherapist.
Participants will be given a description of the functional-
ity, set up and safe usage of the Maxm Skate device and
sensor, and educated on the Maxm Skate exercise pro-
gram. Following this presentation, participants will be is-
sued with a rehabilitation guide to familiarise themselves
with the postoperative exercise program and given the
opportunity to trial the skate package.
Postoperative inpatient phase In the inpatient acute
setting, the Maxm Skate group will receive the Maxm
Skate in addition to standard care as outlined above for
the Standard Care group. The Maxm Skate group may
access inpatient rehabilitation if clinically indicated.
Postoperative outpatient phase Following the in-
patient program, participants in the Maxm Skate pro-
gram will only receive rehabilitation provided through
the Maxm Skate program, described in the Maxm
Skate Rehabilitation Guide (see Additional file 1). This
program includes functional assessment checks at two
weeks and six weeks at the participant’s home. This
will ensure participants are fit to progress through
from Stage One to Stage Two and from Stage Two to
Stage Three of the program. Additional functional
checks will be conducted if required, as assessed by
hospital staff at discharge from hospital. Furthermore,
the checks will allow early identification of partici-
pants who are not advancing and may require add-
itional rehabilitative support.
Participants that are identified as requiring add-
itional physiotherapy will receive such treatment, as
required. Participant functional progress will also be
assessed by the orthopaedic surgeon at the six-week
orthopaedic follow-up appointment. Any additional
outpatient physiotherapy received by a participant
randomised to the Maxm Skate program will be per-
mitted and recorded in the participant study file.
Standard rehabilitative care
Inpatient physiotherapy care provided to patients in hos-
pital will include undertaking the following standard care
exercises: ankle pumps; static quadriceps; supine knee
flexion; inner range quadriceps; straight leg raise; passive
knee extension; seated assisted knee flexion; and active
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knee extension in sitting. Once discharged from hos-
pital, physiotherapy follow-up varies on an individual
basis. The patient is provided four patient-specific options
which are described in the Outpatient Standard Care
Physiotherapy Protocol (FPH) (see Additional file 2).
Study outcomes and participant timeline
The primary objective is ROM achieved at three months
after TKA. Secondary outcomes include patient-reported
outcomes, costs and functional evaluations which will be
collected at multiple time-points up to 12 months after
TKA. Patients will be screened for AE occurrences and
complications from the time of consent to one year
postoperatively. The study assessment schedule in out-
lined in Fig. 1.
Baseline and operative data
Demographic details, knee pathology and medical his-
tory will be collected preoperatively by the clinical nurse
or research delegate.
In order to limit any potential variability attributed
to the prosthetic device, a single total knee pros-
thesis, the Advanced Coated System ACS® Fixed
Bearing System (Oceania Orthopaedics Pty. Ltd.) will
be implanted in all study participants by a single
orthopaedic surgeon (MGL). The medical device will
be implanted using a medial para-patella surgical ap-
proach, using both a cemented and cementless tech-
nique depending on patient characteristics and surgeon
discretion. A midline skin incision will be conducted
for all patients and device-specific instrumentation
will be used.
Fig. 1 Schedule of events
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Patient-reported outcome measures
Patient-reported outcome measures will be assessed
for each group preoperatively and postoperatively at
six weeks, 12 weeks and 12 months. The Oxford Knee
Score (OKS) [24] and Knee Injury and Osteoarthritis
Outcome Score (KOOS) [25] will be used to assess
knee-specific symptoms, pain and function, while the
Euroqol 5 Dimensional Health Survey – Level 5
(EQ-5D-5L) [26] will be used to survey health status.
The Patient Acceptable Symptom State (PASS) [27]
will be used to assess whether the patient feels that
they are at a satisfactory state. Lastly, level of satis-
faction with the outpatient rehabilitation received will
be measured using a 5-point Likert scale as follows:
‘very unsatisfied’; ‘unsatisfied’; ‘neither satisfied nor
unsatisfied’; ‘satisfied’; ‘very satisfied’.
Participants in the Maxm Skate group will also be re-
quired to complete a short questionnaire regarding their
participation in the Maxm rehabilitation program. This
form will be administered at a visit with the Study Co-
ordinator either before or after each functional evalu-
ation with the blinded physiotherapist.
Functional evaluations
The following functional evaluations will be performed by
a blinded physiotherapist preoperatively and at 2, 4, 6, 12,
26 and 52weeks after TKA. Some measures will also be
assessed at day 2 postoperatively; however, these measures
will be taken by an unblinded ward physiotherapist. Func-
tional evaulations are illustrated in Fig. 2.
Joint range of motion and the Visual Analogue Scale
for Pain in flexion and extension In a seated position,
active joint ROM in flexion and extension will be mea-
sured using a standard goniometer. Furthermore, pain at
end-of-range flexion and extension will be measured
using the Visual Analogue Scale (VAS) for Pain. Recov-
ery in knee ROM has been found to plateau 12months
after TKA, therefore end-of-study has been selected to
be 12months postoperatively [28]. Both measures will
also be assessed at day 2 after TKA.
Isometric knee extensor strength, flexor strength and
bilateral hip abduction Hand-held isometric [29–32]
and isokinetic [30, 31, 33, 34] dynamometry has previously
Fig. 2 KangaTech set-up. a Hip abduction: for bilateral hip abduction testing, the participant will also be seated, with the knee flexed at 15° and
lumbo-pelvic-hip complex flexed at 60°. The dynamometry pad will be positioned at the level of the lateral femoral condyles. b Knee extension:
unilateral knee extension performed with participants seated, their knee at 45° flexion and lumbo-pelvic-hip complex at 60° flexion. The dynamometry
pad will be positioned at the level of the lateral malleolus at right angles to the shank/tibia. Each thigh will be secured to the seat with a belt above
the level of the surgical incision (> 10 cm above the supra patella border). c Knee flexion: unilateral knee extension performed with participants seated,
their knee at 45° flexion and lumbo-pelvic-hip complex at 60° flexion. The dynamometry pad will be positioned at the level of the lateral malleolus at
right angles to the shank/tibia. Each thigh will be secured to the seat with a belt above the level of the surgical incision (> 10 cm above the supra
patella border). d Set-up alone at Flinders Private Hospital for use in this study
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been used to safely and effectively measure maximal
quadricep and hamstring muscle strength in OA and
TKR populations. In the present study, a customised
fixed-frame portable dynamometry hardware and soft-
ware system (KangaTech, Melbourne, Australia) will be
used to measure maximum voluntary isometric strength
of the quadriceps, hamstring and hip abductor muscle
groups of each participant.
Maximum voluntary isometric contraction (MVIC)
will be tested for the hip abductors, knee extensors and
knee flexors in a seated position to maximise participant
comfort. Unilateral knee extension and flexion tests will
be performed with participants in a seated position with
their knee at 45° of flexion and with their lumbo-pelvi-
c-hip complex at 60° of flexion. The dynamometry pad
will be positioned at the level of the lateral malleolus at
right angles to the shank/tibia. Each thigh will be se-
cured to the seat with a belt above the level of the surgi-
cal incision (> 10 cm above the supra patella border). For
bilateral hip abduction testing, participants will also be
seated, with the knee flexed at 15° and lumbo-pelvic-hip
complex flexed at 60°. The dynamometry pad will be po-
sitioned at the level of the lateral femoral condyles.
Participants will perform each test in a randomly se-
lected order after having had three gradually ramped
practice/warm-up trials. During these trials, participants
will be asked to produce an isometric contraction at
20%, 50% and 80% of their perceived maximum effort
for 3 s. Participants experiencing any discomfort that is
unusual and/or with an associated pain score of > 3/10
(measured by the VAS – Pain) above their resting level
of pain will be asked not to proceed beyond this level of
force or effort. In this case, the pain limited MVIC will
be recorded.
Participants that warm up without the forementioned
symptoms will proceed to 2 × 5 s MVIC test trials for
each test. Participants will again be advised to limit force
in the presence of discomfort. Time allowed for recovery
between all tests will be 20 s.
Balance test, knee circumference and thigh
circumference This balance test will be performed in a
single-leg standing position, with eyes open. The ability
to maintain balance in this position will be recorded in
seconds.
The participant’s knee and thigh circumference will be
measured using a regular tape measure. The measure-
ments will be taken at two points, specifically at the su-
perior pole of the patella and 15 cm above the superior
pole of the patella. Both measures will also be assessed
at day 2 after TKA.
Clinical performance tests Clinical performance tests,
including the 30-s Chair-Stand Test and the 4 × 10m
Fast Paced Walk Test, will be performed in accordance
with the Osteoarthritis Research Society International
(OARSI) Report guidelines [35]. The tests will be con-
ducted preoperatively and at 2, 4, 6 and 12 weeks, 6 and
12months postoperatively.
Economic evaluation
An economic evaluation assessing the relative cost-ef-
fectiveness of the Maxm Skate rehabilitation device
compared to standard care will be conducted.
This analysis will take the form of an economic evalu-
ation comparing the relative cost-effectiveness analysis
of the Maxm Skate rehabilitation device to standard care
using data collected during the trial. The primary out-
come will be the incremental cost per unit increase in
knee ROM while a secondary outcome will be the incre-
mental cost per quality-adjusted life year (QALY) gained
over the period of the primary study and based on the
EQ-5D-5 L. As an Australian scoring algorithm for the
EQ-5D-5 L is not yet available, the UK value set and
scoring algorithm [36] will be used to convert the indi-
vidual responses to the EQ-5D-5 L at each time point.
Resource use associated with each trial arm will be com-
bined with unit costs for these resources in order to esti-
mate total costs in the trial. Costs will be estimated from
a societal perspective (to include costs borne by private
hospitals and insurance providers, private patients and
social care service providers). Resource use data will in-
clude a number of tests, treatments and investigations
undertaken during in-hospital visits, the frequency and
duration of in-hospital admissions, over the counter
medication, lost productivity, social care services, as well
as quantity and type of consumables and equipment
used. Resource use data to capture patient-specific costs
incurred will only be collected after discharge, using a
resource use questionnaire that will be administered at
2, 4, 6, 12, 26 and 52 weeks. Resource unit costs will be
derived from hospital finance departments and supple-
mented, where necessary, by information from published
source including the Australian Bureau of Statistics and
Australian Refined Diagnosis Related Groups (AR-DRG)
cost weights. Confidence intervals will be presented
around the incremental cost-effectiveness ratios and cost-
effectiveness acceptability curves for varying threshold
values of cost-effectiveness will also be presented [37]. An
assessment of the sensitivity of the results obtained to
variation in measured resource use, effectiveness and/or
unit costs will be undertaken using appropriate determin-
istic and probabilistic sensitivity analyses [38].
Study duration
The study accrual period will be approximately 12
months. Each individual will be followed for 12 months.
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Sample size
A sample size calculation based on achieving 90%
power at two-tailed type 1 error rate of 5% identified
that 110 participants (55 participants per group) would
be required to detect 10° of difference in ROM between
the Maxm Skate program and standard care groups at
three months after TKA assuming a within-group SD
of 16°. The clinically significant difference in ROM of
10° and SD was estimated from parameters described
by Mockford et al. [16], in which the effect of a physio-
therapy regimen on ROM was measured over a one-
year, post-TKA follow-up period. Furthermore, it is
well established that daily activities, including climbing
stairs and standing from a chair, require 90–120° of
flexion, kneeling and squatting 110–165°, and 135° of
flexion to lift from a bath [7–9]. However, patients
rarely achieve > 120° of flexion post TKA and 110° of
flexion is an optimal goal for rehabilitation following
TKA [9–11]. Based on such awareness of requirements
for daily activities, a 10° difference in ROM may delin-
eate between the ability to climb stairs or kneel down
in TKA patients.
In order to account for a potential 5% loss to
follow-up, a total sample of 116 participants (58 per
group) will be recruited.
Statistical methods
All analyses will be conducted on an intention-to-treat
basis and results reported in accordance with CON-
SORT guidelines [39]. The primary endpoint is the
ROM at three months and differences between groups
will be assessed using an independent two-sample t-test
with log-transformation of the outcome, if necessary, in
order to meet the assumptions of normality. If normal-
ity is not achieved using transformation, then the
Mann–Whitney U test will be used. Differences be-
tween groups for the clinical performance tests (30-s
Chair-stand and 4 × 10 m Fast Paced Walk Test) and
data collected on scales such as the OKS will also be
assessed using a two-sample t-test or Wilcoxon Rank
sum test if normality is not achieved. Baseline charac-
teristics, including ROM, will be accounted for in a
sensitivity analysis using mixed effects models that will
also account for any missing data. Where > 10% of data
are missing, multiple imputation using chained equa-
tions will also be used. Functional evaluations that are
assessed at multiple time points will also be assessed
using mixed effects models with an interaction term be-
tween group and visit used to determine differences in
group effects across time. Two-sided hypothesis tests
will be performed for each outcome with a type-1 error
rate of alpha = 0.05 used for determining statistical
significance.
Assessment of safety and criteria for study
discontinuation
The management of AEs that occur during this clinical
trial will be in accordance with the guidelines of the ap-
proving Human Research Ethics Committee.
A safety analysis will be performed by a safety moni-
toring board that includes an independent orthopaedic
field expert when 50% of the participants (58) reach the
primary endpoint, at 12 weeks after TKA.
The primary criteria for discontinuation of the study
will be poor outcomes, indicated by ROM. If > 18 par-
ticipants (30%) in the experimental group (MAXM
Skate program) present a ROM of < 90° at six weeks
after TKA [40], the study will be discontinued. ROM
assessments performed at six weeks will be conducted
by both the study Physiotherapist at the six-week func-
tional follow-up visit (specific to the study), as well as
the treating orthopaedic surgeon at the routine six-week
follow-up visit (routine clinical care at six weeks).
Data management
Clinical study data will be recorded directly on the Case
Report Form (CRF) and will be completed for each par-
ticipant enrolled into the clinical study. The Principal
Investigator or nominated Co-Investigator will review,
approve and sign/date each completed CRF series,
attesting to the accuracy and authenticity of the data
entered.
Clinical study records will be filed in the Clinical Study
Master File in an organised way that will facilitate man-
agement of the clinical study, audit and inspection. The
files will be retained securely before archive and then ar-
chived for a period of not less than 15 years to allow for
audit and inspection by regulatory authorities upon
request.
The Principal Investigator will permit direct access of
the study monitors, the appropriate Human Research
Ethics Committee and appropriate regulatory authorities
to the study data when required.
Ethics and dissemination
This study received ethical approval from The Bellberry
Human Research Ethics Committee on 24 September
2018. Any approved amendments made to the study
protocol will be updated on the trial registry and the
Therapeutic Goods Administration Clinical Trial Notifi-
cation record, if appropriate.
Throughout the trial, investigators will endeavour to
present preliminary findings at national and inter-
national orthopaedic conferences. At the conclusion of
the trial, results will be prepared for presentation and
publication in scientific journals.
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Discussion
With the increasing demand for TKA, further research
must explore safe, optimal, cost-effective alternatives for
physical rehabilitation following TKA. This single-
blinded RCT will compare safety, efficacy and cost-
effectiveness of a novel home-based approach, the Maxm
Skate rehabilitation program to standard rehabilitative
care following TKA.
Study limitations
As is well discussed in the literature, there is potential for
single-centre studies to have limited external validity. In
the case of the present study, this may be considered a
limitation given the enrolment of privately insured pa-
tients and the rehabilitation pathways offered to them in
isolation, as compared to the rehabilitation pathways that
may be available or typically selected in public healthcare
centres. As such, in this study we are only capable of cap-
turing the postoperative rehabilitation pathways that are
routinely selected at Flinders Private Hospital. Interest-
ingly, in Australia the mean discharge of privately insured
TKA and THA patients to inpatient rehabilitation facil-
ities is 40.1%, compared to 20% in public patients [41]. As
such, this study will capture the frequency, length and
type of rehabilitation the study participants receive, in the
hopes of improving transparency and generalisability of
care. In addition, the study will also be recruiting a single
surgeon’s patients, which once again may reduce general-
isability across surgeons within and across centres. Despite
this, in order to reduce any potential bias associated with
a single surgeon’s patient cohort, the study orthopaedic
surgeon is to be completely blinded to treatment
allocation and, wherever possible, blinded to study partici-
pation altogether. Previous studies have addressed the
heterogeneity of standard care options for rehabilitation
between private hospitals in Australia [42] and this also
presents in our study as a potential limitation. Further to
this, there may also be a deal of heterogeneity across the
Maxm Skate group participants, as despite their allocation
and use of the Maxm Skate exercise program, should they
feel it necessary to receive additional physiotherapy to as-
sist in their recovery, they are able to do so. These varia-
tions in rehabilitative care are unavoidable to provide
equal and consistent clinical care opportunities across all
patients. In order to account for such heterogeneity in the
rehabilitative pathway, a clear outline of the frequency,
duration and type of treatment received by each partici-
pant will be documented at each follow-up visit with the
Study Coordinator. Furthermore, at study conclusion,
per-protocol analyses will be performed within the Maxm
Skate group to distinguish any differences observed be-
tween participants receiving any physiotherapy care
additional to the Maxm Skate exercise program. Such
‘as-treated’ grouping may assist in addressing the recog-
nised limitation of participant receipt of additional care
masking any potential benefit of the Maxm Skate exercise
program. Despite the above recognised limitations of this
study, we believe this RCT will provide sound evidence
describing the potential differences observed over the
course of different rehabilitative pathways of TKA patients
in our centre.
Trial status
This publication is based on the study protocol version
08, dated 15 October 2018. Participant recruitment is
anticipated to commence in October 2018, with an ap-
proximate recruitment period of 12 months. Details of
the Maxm Skate study team are listed in Table 1.
Table 1 Maxm Skate Study team
Name Role on team Affiliation
Professor Jeganath Krishnan Principle Investigator College of Medicine and Public Health, Flinders University, Adelaide,
South Australia, Australia; The International Musculoskeletal Research
Institute Inc., Adelaide, Australia
Dr Matthew G. Liptak Co-investigator; treating Orthopaedic Surgeon Orthopaedic SA, Adelaide, Australia
Annika Theodoulou Clinical Trial Coordinator (pre-recruitment [study
design and set-up])
College of Medicine and Public Health, Flinders University, Adelaide,
South Australia, Australia; The International Musculoskeletal Research
Institute Inc., Adelaide, Australia
Dr Kristen Georgiou Clinical Trial Coordinator (during recruitment) College of Medicine and Public Health, Flinders University, Adelaide,
South Australia, Australia; The International Musculoskeletal Research
Institute Inc., Adelaide, Australia
Scott W. Hinrichs Co-investigator; blinded physiotherapist Flinders Private Hospital, Adelaide, Australia
Dr Steve Saunders Physiotherapist; development of Maxm Skate
rehabilitation program
Adjunct researcher – University of South Australia
Director – Saunders Sports and Spinal
Science and Medical Coordinator – Adelaide Football Club
A/Prof Billingsley Kaambwa Health Economist Health Economics Unit, College of Medicine and Public Health
Flinders University
Prof Richard J. Woodman Biostatistician Flinders Centre for Epidemiology and Biostatistics, College of
Medicine, Flinders University
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This protocol publication has been prepared on the
basis of the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines. This
SPIRIT Checklist is available in the Additional file 3.
Additional files
Additional file 1: Maxm Skate Rehabilitation Guide. (PDF 2897 kb)
Additional file 2: Outpatient Standard Care Physiotherapy Protocol
(FPH). (DOCX 15 kb)
Additional file 3: SPIRIT Checklist. (DOC 123 kb)
Abbreviations
AE: Adverse event; App: iOS Application; AR-DRG: Australian Bureau of Statistics
and Australian Refined Diagnosis Related Groups; CRF: Case Report Form; EQ – 5D
5L: Euroqol 5 Dimensional Health Survey – Level 5; FPH: Flinders Private Hospital;
iOS: iPhone Operating System; KOOS: Knee Injury and Osteoarthritis Outcome
Score; MVIC: Maximum voluntary isometric contraction; OARSI: Osteoarthritis
Research Society International; OKS: Oxford Knee Score; PASS: Patient
Acceptable Symptom State; QALY: Quality-adjusted life year; RCT: Randomised
controlled trial; ROM: Range of motion; TKA: Total knee arthroplasty; UK: United
Kingdom; VAS – Pain: Visual Analogue Scale for Pain
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